BMO Capital lowers Scholar Rock stock price target to $45 on Novo Catalent concerns

Published 07/08/2025, 13:58
BMO Capital lowers Scholar Rock stock price target to $45 on Novo Catalent concerns

Investing.com - BMO Capital has lowered its price target on Scholar Rock (NASDAQ:SRRK) to $45.00 from $57.00 while maintaining an Outperform rating on the stock. Despite the target reduction, SRRK has demonstrated remarkable strength with a 319% return over the past year. According to InvestingPro data, the stock currently trades at $34.62, with analyst targets ranging from $46 to $57.

The price target reduction comes as BMO Capital analyst Etzer Darout cited ongoing problems at Novo’s Catalent (NYSE:CTLT) facilities that could potentially impact the PDUFA date for apitegromab, Scholar Rock’s investigational drug.

Apitegromab is produced within Novo’s Catalent facilities, which were previously flagged for FDA observations during a pre-approval site visit, creating uncertainty around the drug’s regulatory timeline.

The analyst noted that last week, Regeneron (NASDAQ:REGN) received a Complete Response Letter (CRL) for odronextamab approval and experienced a delayed response for the label extension of Eylea HD Q4W dosing, suggesting broader regulatory challenges related to Novo Catalent facilities.

While Scholar Rock’s management has expressed confidence in apitegromab’s approval, BMO Capital indicates that delays are possible "given late CMC issue identification and proximity to PDUFA," leading to the reduced price target.

In other recent news, Scholar Rock reported its second-quarter 2025 earnings, which showed an EPS of -0.98. This result was below the expected EPS of -0.66, representing a 48.48% negative surprise. The earnings miss has raised concerns among investors regarding the company’s financial performance. Additionally, Raymond (NSE:RYMD) James has maintained its Strong Buy rating for Scholar Rock, with a price target of $53.00. This decision comes as the company approaches a significant milestone with the upcoming PDUFA date for its drug candidate, apitegromab, on September 22nd. These developments highlight key areas of interest for investors monitoring Scholar Rock’s progress.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.